治疗药物监测与药代动力学/药效学优化β-内酰胺类抗生素治疗深部感染的系统综述
结果显示PK/PD靶值定义、达标率和剂量调整差异大,仅1项研究设非TDM对照组且无显著差异,3项研究显示TDM指导有改善趋势。结论认为现有证据受方法学异质性和研究质量差限制,需设计良好的试验确立TDM的临床价值。
要点
- 深部感染中β-内酰胺类TDM的临床获益证据有限,研究异质性大且质量普遍较差。
- TDM常因担心标准剂量毒性而导致剂量下调,而非单纯为达标而增量。
- 仅1项设非TDM对照的研究报告临床结局无显著差异,3项研究显示改善趋势。
核心结论
- 现有支持深部感染中使用β-内酰胺类TDM的证据受方法学异质性和研究质量差限制,需良好设计的试验确立其临床效用。
主要发现
- 仅1项研究包含非TDM对照组,作者报告临床结局无显著差异。
- 3项研究显示TDM指导给药有改善临床结局的趋势。
- TDM常因担心标准剂量下β-内酰胺类抗生素毒性而导致剂量下调。
- PK/PD靶值定义、达标情况、剂量调整和结局报告存在显著变异。
临床怎么用
- 在深部感染患者中,TDM指导的β-内酰胺类剂量调整可能常导致剂量下调,需权衡疗效与毒性。
- 当前证据尚不足以常规推荐TDM用于所有深部感染患者,临床决策应个体化并结合PK/PD原则。
局限性
- 研究间PK/PD靶值定义和结局报告异质性大,多数研究质量差且缺乏非TDM对照。
- 仅1项研究设非TDM对照组,无法可靠评估TDM对临床结局的独立影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic drug monitoring (TDM) may help optimize beta-lactam antibiotic dosing in patients with deep-seated infections. However, its impact on clinical outcomes remains unclear. OBJECTIVE: The objective of this review was to evaluate the existing evidence on the role of TDM and pharmacokinetic/pharmacodynamic (PK/PD)-guided optimization of beta-lactam antibiotic dosing in achieving PK/PD targets, and improving clinical outcomes in patients with deep-seated infections. METHODS: We conducted a systematic review of studies reporting on beta-lactam TDM, PK/PD target attainment, and clinical outcomes in adult (≥18 years) patients with confirmed deep-seated infections, including complex bacteraemias with a suspected or proven deep-seated source, infective endocarditis, bone and joint infection, and epidural abscess. The search was conducted using MEDLINE (via PubMed), Embase, CINAHL and CENTRAL from inception to June 2025. RESULTS: Twelve studies were included in the final analysis. Considerable variability was observed in PK/PD target definitions and attainment, dosing adjustments and outcome reporting. Eleven of the twelve studies were rated as poor quality on the Newcastle-Ottawa Scale due to lack of comparability. Only one study included a non-TDM comparator group and the authors reported no significant difference in clinical outcomes. Three studies showed a trend towards improved clinical outcomes with TDM-guided dosing. TDM frequently led to dose reductions due to concerns of beta-lactam antibiotic toxicity with standard dosing. CONCLUSION: Current evidence supporting beta-lactam antibiotic TDM in deep-seated infections is limited by methodological heterogeneity and poor study quality. Well-designed trials are needed to establish the clinical utility of TDM in this setting.
引用
- Vale C, Sime FB, Cotta MO, et al. Therapeutic drug monitoring and the role of pharmacokinetics/pharmacodynamics in optimizing beta-lactam antibiotic dosing for deep-seated infections: a systematic review. J Antimicrob Chemother. 2026. PMID: 41982169. doi:10.1093/jac/dkag142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。